US 12,304,932 B2
PACAP stabilized peptide
Shinnosuke Machida, Osaka (JP); and Takeshi Nakajima, Osaka (JP)
Assigned to SENJU PHARMACEUTICAL CO., LTD., Osaka (JP)
Appl. No. 16/763,732
Filed by SENJU PHARMACEUTICAL CO., LTD., Osaka (JP)
PCT Filed Nov. 14, 2018, PCT No. PCT/JP2018/042196
§ 371(c)(1), (2) Date May 13, 2020,
PCT Pub. No. WO2019/098254, PCT Pub. Date May 23, 2019.
Claims priority of application No. 2017-219181 (JP), filed on Nov. 14, 2017.
Prior Publication US 2020/0347107 A1, Nov. 5, 2020
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/4705 (2013.01) [A61K 38/00 (2013.01)] 6 Claims
 
1. A peptide consisting of a sequence or modified sequence wherein, in the sequence represented by the following formula:
 
 (SEQ ID NO: 3)
 
 H-X1-D-G-I-F-T-D-X2-Y-X3-R-Y-R-X4-X5-X6-A-X7-X8-
 
 
 
 X9-Y-L-A-A-V-X10
wherein:
X1, X2 and X3 are alanine or serine,
X4, X8 and X9 are lysine or arginine,
X5 is glutamine, alanine or an amino acid having the amide of glutamine replaced with tetrazole,
X6 is methionine, norleucine, alanine or leucine,
X7 is valine or alanine, and
X10 is leucine or alanine,
wherein the carboxy group of the aspartic acid residue at position 3 and/or position 8 is replaced with tetrazole, and optionally one, two or three amino acids is deleted from C-terminus of the sequence of SEQ ID NO: 3, or any one sequence selected from the group consisting of:
 
 (SEQ ID NO: 37)
 
 GKRYKQRVKNK;
 
 
 
 (SEQ ID NO: 38)
 
 GKRYKQRVKN;
 
 
 
 (SEQ ID NO: 39)
 
 GKRYKQRVK;
 
 
 
 (SEQ ID NO: 40)
 
 GKRYKQRV;
 
 
 
 (SEQ ID NO: 41)
 
 GKRYKQR;
 
 
 
 (SEQ ID NO: 42)
 
 GKRYKQ;
 
 
 
 (SEQ ID NO: 43)
 
 GKRYK;
 
 
 
 (SEQ ID NO: 44)
 
 GKRY
 
 
 
 GKR;
 
 
 
 GRR;
 
 
 
 GK;
 
 and
 
 
 
 GR
 
 
 
 G;
is added at C-terminus of the sequence of SEQ ID NO: 3.